CDMO for Advanced Medicine
DiNAMIQS was established in 2021 and spun out from DiNAQOR as an independent entity in 2023. Since then, it has been acquired with majority equity by Siegfried, one of the leading Contract Development and Manufacturing Organizations (CDMOs).
Siegfried DiNAMIQS specializes in advanced medicine production, providing GMP-compatible capabilities and scalable viral vector manufacturing. Our partner accelerates development timelines, reduces costs and risks, and ensures the reliable delivery of high-quality vectors for R&D through clinical stages.
Human Tissue & Stem Cell Research Services
DiNABIOS is our dedicated human tissue and stem cell research services company, focused on advancing translational science through the development of sophisticated engineered tissue models. By leveraging its proprietary AI-driven platforms, DiNABIOS enhances the accuracy and efficiency of drug discovery, preclinical testing, and tissue therapy development. DiNABIOS’ expertise enables the creation of human-relevant models that improve predictability, reduce development timelines, and support innovative approaches in personalized medicine and regenerative therapies.
Drug Delivery MedTech
At the forefront of medicine and technology, DiNATEQ focuses on the development of cutting-edge drug delivery systems, including sophisticated loco-regional perfusion devices. These devices are engineered to deliver therapeutics directly to specific organs or tissues with high precision, significantly improving treatment efficacy while reducing systemic exposure and off-target effects. By enabling localized, targeted delivery, these systems also support repeat dosing protocols, increasing treatment flexibility and patient safety. DiNATEQ’s innovative delivery solutions aim to offer more effective, safer, and patient-friendly treatment options across a range of medical conditions.
N=1 Precision Oncology
DAiNA is creating a living model of precision oncology through integrating the full spectrum of tumor biology from genomics and proteomics with spatial pathology into an AI-driven engine that learns, predicts, and adapts to each patient’s cancer in real time. As artificial intelligence and deep biology converge, DAiNA will help lead the shift toward truly individualized cancer care.